Lauren E. Abrey - Concepedia

Author

Lauren E. Abrey

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

A. Reiner, Abrey, Lauren E, K. Hoang-Xuan, L ABREY, L E Abrey, L. Abrey, L. E. Abrey, L.E. Abrey, Lauren Abrey, Lauren E Abrey

343

Publications

25.9K

Citations

H-Index

118

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center University of California, Los Angeles The University of Texas MD Anderson Cancer Center University of California, San Francisco Dana-Farber Cancer Institute

About

Lauren E. Abrey is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, neuro-oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	42	76	6.6K
2	Health Sciences	19	29	2.9K
3	Social Sciences	5	5	444
4	Public Health	2	2	140
5	Allergy	1	1	53

Lauren E. Abrey

153

Publications

23.1K

Citations

H-Index

Page 1

	Year	Citations
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma Olivier Chinot, Wolfgang Wick, Warren Mason, New England Journal of Medicine	2014	2.4K
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma Henry S. Friedman, Michael D. Prados, Patrick Y. Wen, Journal of Clinical Oncology	2009	2.4K
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma Lauren E. Abrey, Tracy T. Batchelor, Andrés J.M. Ferreri, Journal of Clinical Oncology Pcnsl SurvivorsPrimary Cns LymphomaPathologyGliomaResponse Criteria	2005	882
Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model Lauren E. Abrey, Leah Ben‐Porat, Katherine S. Panageas, Journal of Clinical Oncology	2006	607
Treatment for Primary CNS Lymphoma: The Next Step Lauren E. Abrey, Joachim Yahalom, Lisa M. DeAngelis Journal of Clinical Oncology	2000	605
Long-term survival in primary CNS lymphoma. Lauren E. Abrey, Lisa M. DeAngelis, Joachim Yahalom Journal of Clinical Oncology	1998	577
Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome Patrick G. Morris, Denise D. Correa, Joachim Yahalom, Journal of Clinical Oncology	2013	476
Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 Patrick Y. Wen, W.K. Alfred Yung, Kathleen R. Lamborn, Clinical Cancer Research	2006	426
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas Kathleen R. Lamborn, W.K. Alfred Yung, Susan M. Chang, Neuro-Oncology Progression-free SurvivalGrade Iii GliomasCancer ManagementPrognosisImportant End Point	2008	416
Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma Gaurav Shah, Joachim Yahalom, Denise D. Correa, Journal of Clinical Oncology	2007	397

Page 1